GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1283 Prasugrel hydrochlorideSummary: P2 Receptor inhibitor
-
B2166 TicagrelorSummary: P2Y12 receptor antagonist
-
B2167 MRS 2578Summary: P2Y6 receptor antagonist,potent and selective
-
B5507 PSB 0739Summary: P2Y12 receptor antagonist
-
B7508 NF 340Summary: P2Y11 antagonist
-
B4634 AZD1283Target: Purinergic (P2Y) ReceptorsSummary: Potent P2Y12 antagonist
-
B7080 MRS 2693 trisodium saltSummary: P2Y6 agonist
-
B7158 PSB 0474Summary: P2Y6 receptor agonist
-
B7218 MRS 2690Summary: P2Y14 receptor agonist
-
B7041 MRS 2211Summary: P2Y13 receptor antagonist